dwb2023/gtopdb-target-family-interaction-detail huggingface dataset:
Target family: Taste 2 receptors (type: gpcr)
Target: <i>TAS2R40</i>

Ligand: quinine (Natural product)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (2005, as quinine sulfate, previous history unspecified)
Primary target: no
Median affinity:  -
Reference (Journal): The molecular receptive ranges of human TAS2R bitter taste receptors.
Published in: Chem Senses

Ligand: GIV3727 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 5.199999809265137 pIC50
Reference (Journal): Modulation of bitter taste perception by a small molecule hTAS2R antagonist.
Published in: Curr Biol

Ligand: dapsone (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (1979), UK (1988)
Primary target: no
Median affinity:  -
Reference (Journal): The molecular receptive ranges of human TAS2R bitter taste receptors.
Published in: Chem Senses

Ligand: cohumulone (Natural product)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 7.400000095367432 pEC50
Reference (Journal): Three TAS2R Bitter Taste Receptors Mediate the Psychophysical Responses to Bitter Compounds of Hops (Humulus lupulus L.) and Beer
Published in: Chemosensory Perception
Target family: Taste 2 receptors (type: gpcr)
Target: <i>TAS2R3</i>

Ligand: chloroquine (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (1949), UK (2000)
Primary target: no
Median affinity:  -
Reference (Journal): The molecular receptive ranges of human TAS2R bitter taste receptors.
Published in: Chem Senses
Target family: Taste 2 receptors (type: gpcr)
Target: <i>TAS2R38</i>

Ligand: sinigrin (Natural product)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): The molecular receptive ranges of human TAS2R bitter taste receptors.
Published in: Chem Senses

Ligand: propylthiouracil (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (1947)
Primary target: no
Median affinity: 5.679999828338623 pEC50
Reference (Journal): The molecular basis of individual differences in phenylthiocarbamide and propylthiouracil bitterness perception.
Published in: Curr Biol

Ligand: probenecid (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1951)
Primary target: no
Median affinity: 3.680000066757202 pIC50
Reference (Journal): Probenecid inhibits the human bitter taste receptor TAS2R16 and suppresses bitter perception of salicin.
Published in: PLoS One

Ligand: phenylthiocarbamide (Natural product)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 5.679999828338623 pEC50
Reference (Journal): The molecular basis of individual differences in phenylthiocarbamide and propylthiouracil bitterness perception.
Published in: Curr Biol

Ligand: methimazole (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (1950)
Primary target: no
Median affinity: 4.010000228881836 pEC50
Reference (Journal): Genetic, functional, and phenotypic diversity in TAS2R38-mediated bitter taste perception.
Published in: Chem Senses

Ligand: goitrin (Natural product)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 4.190000057220459 pEC50
Reference (Journal): Genetics and bitter taste responses to goitrin, a plant toxin found in vegetables.
Published in: Chem Senses
Target family: Taste 2 receptors (type: gpcr)
Target: <i>TAS2R31</i>

Ligand: sakuranetin (Natural product)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 5.260000228881836 pIC50
Reference (Journal): In vitro evaluation of flavonoids from Eriodictyon californicum for antagonist activity against the bitterness receptor hTAS2R31.
Published in: J Agric Food Chem

Ligand: saccharin (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 2.9600000381469727 pEC50
Reference (Journal): Bitter taste receptors for saccharin and acesulfame K.
Published in: J Neurosci

Ligand: GIV3727 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 5.460000038146973 pIC50
Reference (Journal): Modulation of bitter taste perception by a small molecule hTAS2R antagonist.
Published in: Curr Biol

Ligand: famotidine (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (1986)
Primary target: no
Median affinity:  -
Reference (Journal): The molecular receptive ranges of human TAS2R bitter taste receptors.
Published in: Chem Senses

Ligand: cyclamate (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 1.7899999618530273 pIC50
Reference (Journal): Blends of Non-caloric Sweeteners Saccharin and Cyclamate Show Reduced Off-Taste due to TAS2R Bitter Receptor Inhibition.
Published in: Cell Chem Biol

Ligand: aristolochic acid (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 6.349999904632568 pEC50
Reference (Journal): Bitter taste receptors for saccharin and acesulfame K.
Published in: J Neurosci

Ligand: acesulfame (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 2.5999999046325684 pEC50
Reference (Journal): Bitter taste receptors for saccharin and acesulfame K.
Published in: J Neurosci
Target family: Taste 2 receptors (type: gpcr)
Target: <i>TAS2R30</i>

Ligand: denatonium (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 6.570000171661377 pEC50
Reference (Journal): The molecular receptive ranges of human TAS2R bitter taste receptors.
Published in: Chem Senses

Ligand: amarogentin (Natural product)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 6.389999866485596 pEC50
Reference (Journal): Receptor Polymorphism and Genomic Structure Interact to Shape Bitter Taste Perception.
Published in: PLoS Genet

Ligand: absinthin (Natural product)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 6.400000095367432 pEC50
Reference (Journal): The molecular receptive ranges of human TAS2R bitter taste receptors.
Published in: Chem Senses
Target family: Taste 2 receptors (type: gpcr)
Target: <i>TAS2R20</i>

Ligand: vanillin (Natural product)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 3.2799999713897705 pEC50
Reference (Journal): Vanillin Activates Human Bitter Taste Receptors TAS2R14, TAS2R20, and TAS2R39.
Published in: Front Nutr

Ligand: tobramycin (Natural product)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (1975), EMA (2011)
Primary target: no
Median affinity: 4.289999961853027 pEC50
Reference (Journal): Chemosensory bitter taste receptors (T2Rs) are activated by multiple antibiotics.
Published in: FASEB J

Ligand: ritanserin (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 5.21999979019165 pEC50
Reference (Journal): Phytochemicals from Ruta graveolens Activate TAS2R Bitter Taste Receptors and TRP Channels Involved in Gustation and Nociception.
Published in: Molecules

Ligand: diphenidol (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Primary target: no
Median affinity:  -
Reference (Journal): The molecular receptive ranges of human TAS2R bitter taste receptors.
Published in: Chem Senses

Ligand: cromoglicic acid (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (1984)
Primary target: no
Median affinity: 4.349999904632568 pEC50
Reference (Journal): The molecular receptive ranges of human TAS2R bitter taste receptors.
Published in: Chem Senses
Target family: Taste 2 receptors (type: gpcr)
Target: <i>TAS2R1</i>

Ligand: L-Trp-Trp-Trp (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Amino acids and peptides activate at least five members of the human bitter taste receptor family.
Published in: J Agric Food Chem

Ligand: L-Phe-Phe-Phe (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 3.430000066757202 pEC50
Reference (Journal): Bitter taste receptor T2R1 is activated by dipeptides and tripeptides.
Published in: Biochem Biophys Res Commun

Ligand: dextromethorphan (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (no history prior to 1982)
Primary target: no
Median affinity:  -
Reference (Journal): The molecular receptive ranges of human TAS2R bitter taste receptors.
Published in: Chem Senses

Ligand: cohumulone (Natural product)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 6.699999809265137 pEC50
Reference (Journal): Three TAS2R Bitter Taste Receptors Mediate the Psychophysical Responses to Bitter Compounds of Hops (Humulus lupulus L.) and Beer
Published in: Chemosensory Perception
Target family: Taste 2 receptors (type: gpcr)
Target: <i>TAS2R16</i>

Ligand: sinigrin (Natural product)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): The molecular receptive ranges of human TAS2R bitter taste receptors.
Published in: Chem Senses

Ligand: salicin (Natural product)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 2.8499999046325684 pEC50
Reference (Journal): The human TAS2R16 receptor mediates bitter taste in response to beta-glucopyranosides.
Published in: Nat Genet

Ligand: probenecid (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1951)
Primary target: no
Median affinity: 3.5299999713897705 pIC50
Reference (Journal): Probenecid inhibits the human bitter taste receptor TAS2R16 and suppresses bitter perception of salicin.
Published in: PLoS One

Ligand: Phenyl-β-D-glucopyranoside (Natural product)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 2.9600000381469727 pEC50
Reference (Journal): The human TAS2R16 receptor mediates bitter taste in response to beta-glucopyranosides.
Published in: Nat Genet

Ligand: D-(-)-Amygdalin (Natural product)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 1.7000000476837158 pEC50
Reference (Journal): The human TAS2R16 receptor mediates bitter taste in response to beta-glucopyranosides.
Published in: Nat Genet

Ligand: beta-gentiobiose (Natural product)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 2.4200000762939453 pEC50
Reference (Journal): The human bitter taste receptor, hTAS2R16, discriminates slight differences in the configuration of disaccharides.
Published in: Biochem Biophys Res Commun

Ligand: 4-Nitrophenyl-β-D-mannopyranoside (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 3.190000057220459 pEC50
Reference (Journal): The Bitter Taste Receptor TAS2R16 Achieves High Specificity and Accommodates Diverse Glycoside Ligands by using a Two-faced Binding Pocket.
Published in: Sci Rep
Target family: Taste 2 receptors (type: gpcr)
Target: <i>TAS2R13</i>

Ligand: diphenidol (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Primary target: no
Median affinity:  -
Reference (Journal): The molecular receptive ranges of human TAS2R bitter taste receptors.
Published in: Chem Senses

Ligand: denatonium (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): The molecular receptive ranges of human TAS2R bitter taste receptors.
Published in: Chem Senses
Target family: Taste 2 receptors (type: gpcr)
Target: <i>TAS2R10</i>

Ligand: bergapten (Natural product)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 5.550000190734863 pEC50
Reference (Journal): Phytochemicals from Ruta graveolens Activate TAS2R Bitter Taste Receptors and TRP Channels Involved in Gustation and Nociception.
Published in: Molecules
Target family: Tau tubulin kinase (TTBK) family (type: enzyme)
Target: tau tubulin kinase 1

Ligand: AMG28 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.699999809265137 pIC50
Reference (Journal): Discovery of Potent and Brain-Penetrant Tau Tubulin Kinase 1 (TTBK1) Inhibitors that Lower Tau Phosphorylation In Vivo.
Published in: J Med Chem
Target family: TEAD (transcriptional enhanced associate domain) transcription factors (type: other_protein)
Target: TEA domain transcription factor 3

Ligand: IAG933 (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers.
Published in: Nat Cancer

Ligand: GNE-7883 (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 7 pIC50
Reference (Journal): An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance.
Published in: Nat Cancer
Target family: TEAD (transcriptional enhanced associate domain) transcription factors (type: other_protein)
Target: TEA domain transcription factor 2

Ligand: IAG933 (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers.
Published in: Nat Cancer

Ligand: GNE-7883 (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 8 pIC50
Reference (Journal): An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance.
Published in: Nat Cancer
Target family: TEAD (transcriptional enhanced associate domain) transcription factors (type: other_protein)
Target: TEA domain transcription factor 1

Ligand: IAG933 (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers.
Published in: Nat Cancer

Ligand: GNE-7883 (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 7.300000190734863 pIC50
Reference (Journal): An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance.
Published in: Nat Cancer

Ligand: GNE-7883 (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 7.400000095367432 pIC50
Reference (Journal): An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance.
Published in: Nat Cancer
Target family: TEAD (transcriptional enhanced associate domain) transcription factors (type: other_protein)
Target: TEA domain transcription factor 4

Ligand: IAG933 (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers.
Published in: Nat Cancer

Ligand: GNE-7883 (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 7.519999980926514 pIC50
Reference (Journal): An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance.
Published in: Nat Cancer
Target family: TEAD (transcriptional enhanced associate domain) transcription factors (type: other_protein)
Target: TEA domain transcription factor 3

Ligand: GNE-7883 (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 7.050000190734863 pIC50
Reference (Journal): An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance.
Published in: Nat Cancer
Target family: Tec family (type: enzyme)
Target: IL2 inducible T cell kinase

Ligand: WZ4002 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.369999885559082 pKd
Reference (Journal): Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.
Published in: Nature

Ligand: soquelitinib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8 pIC50
Reference (Patent): Compounds and methods for modulating interleukin-2-inducible t-cell kinase

Ligand: PRN694 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 9.520000457763672 pIC50
Reference (Journal): Targeting interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK) using a novel covalent inhibitor PRN694.
Published in: J Biol Chem

Ligand: ibrutinib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2013), EMA (2014)
Primary target: no
Median affinity: 8.3100004196167 pIC50
Reference (Journal): Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
Published in: N Engl J Med

Ligand: GNE-4997 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 10.050000190734863 pKi
Reference (Journal): Tetrahydroindazoles as Interleukin-2 Inducible T-Cell Kinase Inhibitors. Part II. Second-Generation Analogues with Enhanced Potency, Selectivity, and Pharmacodynamic Modulation in Vivo.
Published in: J Med Chem

Ligand: compound 7 [PMID: 22464456] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 9.520000457763672 pIC50
Reference (Journal): X-ray crystallographic structure-based design of selective thienopyrazole inhibitors for interleukin-2-inducible tyrosine kinase.
Published in: Bioorg Med Chem Lett

Ligand: compound 4g [PMID: 21316219] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.21999979019165 pIC50
Reference (Journal): Optimisation of ITK inhibitors through successive iterative design cycles.
Published in: Bioorg Med Chem Lett

Ligand: compound 25 [PMID: 31260299] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.510000228881836 pIC50
Reference (Journal): Discovery of 4-Aminoquinoline-3-carboxamide Derivatives as Potent Reversible Bruton's Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis.
Published in: J Med Chem

Ligand: BMS-509744 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.71999979019165 pIC50
Reference (Journal): Discovery and SAR of 2-amino-5-(thioaryl)thiazoles as potent and selective Itk inhibitors.
Published in: Bioorg Med Chem Lett
Target family: Tec family (type: enzyme)
Target: Bruton tyrosine kinase

Ligand: BIIB068 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9 pIC50
Reference (Journal): Discovery of BIIB068: A Selective, Potent, Reversible Bruton's Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases.
Published in: J Med Chem

Ligand: atuzabrutinib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.699999809265137 pIC50
Reference (Patent): Tyrosine kinase inhibitors

Ligand: acalabrutinib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2017), EMA (2020)
Primary target: yes
Median affinity: 8 pEC50
Reference (Patent): 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk inhibitors.

Ligand: acalabrutinib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2017), EMA (2020)
Primary target: yes
Median affinity: 8.289999961853027 pIC50
Reference (Journal): Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
Published in: N Engl J Med

Ligand: abivertinib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9.399999618530273 pIC50
Reference (Journal): AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer Patients.
Published in: Mol Cancer Ther
Target family: Tec family (type: enzyme)
Target: Bruton tyrosine kinase

Ligand: CHMFL-BTK-11 (Synthetic organic)
Interaction type: Inhibitor
Action: Irreversible inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.570000171661377 pIC50
Reference (Journal): Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model.
Published in: Sci Rep
Target family: Tec family (type: enzyme)
Target: IL2 inducible T cell kinase

Ligand: acalabrutinib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2017), EMA (2020)
Primary target: no
Median affinity: 6 pIC50
Reference (Journal): Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
Published in: N Engl J Med